T. Rowe Price Associates
RXST icon

T. Rowe Price Associates’s RxSight RXST Stock Holding History

T. Rowe Price Associates’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$218K Buy
45,127
+5,997
+15% +$36.2K ﹤0.01% 2980
2026
Q1 		$242K Buy
39,130
+7,374
+23% +$61.2K ﹤0.01% 2767
2025
Q4 		$331K Sell
31,756
-1,772
-5% -$17.8K ﹤0.01% 2601
2025
Q3 		$302K Buy
33,528
+10,426
+45% +$91.5K ﹤0.01% 2603
2025
Q2 		$301K Buy
23,102
+5,354
+30% +$80.5K ﹤0.01% 2526
2025
Q1 		$449K Buy
17,748
+1,564
+10% +$46.5K ﹤0.01% 2290
2024
Q4 		$557K Sell
16,184
-23,863
-60% -$1.08M ﹤0.01% 2246
2024
Q3 		$1.98M Buy
40,047
+2,840
+8% +$146K ﹤0.01% 1642
2024
Q2 		$2.24M Sell
37,207
-23,701
-39% -$1.35M ﹤0.01% 1500
2024
Q1 		$3.14M Buy
60,908
+994
+2% +$48.8K ﹤0.01% 1369
2023
Q4 		$2.42M Buy
59,914
+34,003
+131% +$997K ﹤0.01% 1437
2023
Q3 		$724K Buy
25,911
+622
+2% +$18.5K ﹤0.01% 1945
2023
Q2 		$730K Buy
+25,289
New +$563K ﹤0.01% 1963

Other funds holding RXST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.66B AUM 39.91% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

T. Rowe Price Associates's RXST Position: Q2 2026 in Review

T. Rowe Price Associates increased its RxSight (RXST) stake by 15% in Q2 2026, buying an estimated $36.2K and bringing the position to 45,127 shares worth $218K. The position accounts for ﹤0.01% of the portfolio, ranked #2980.

T. Rowe Price Associates first reported a position in RXST in Q2 2023 and has held it in 13 quarters since. The position peaked at $3.14M in Q1 2024. 152 funds tracked by Wall St. Rank hold RXST as of Q2 2026.

  • T. Rowe Price Associates held 45,127 shares of RxSight worth $218K as of Q2 2026.
  • T. Rowe Price Associates bought 5,997 RxSight shares in Q2 2026, an estimated $36.2K.
  • RxSight made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2980 holding.
  • T. Rowe Price Associates first reported a position in RxSight in Q2 2023 and has held it in 13 quarters since.
  • T. Rowe Price Associates's RxSight position peaked at $3.14M in Q1 2024.
  • 152 funds tracked by Wall St. Rank held RxSight as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.